Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 (DoDNAC)
Neurofibromatosis 1
About this trial
This is an interventional treatment trial for Neurofibromatosis 1
Eligibility Criteria
Inclusion Criteria:
- Male and females aged 8 - 16 years (up to 16 years and 6 months) at time of enrollment
- Meets NIH diagnostic criteria for NF1
- Abnormal PANESS study (score at or above the age/sex-based mean)
- Participants must have a full scale intelligence quotient (IQ) of 70 or above, as determined by neurocognitive testing within the last 3 years or during the enrollment process
- Participants on stimulant or any other psychotropic medication should stay on a stable dose (no change in dose) for at least 30 days before entering the study. A stable dose should be maintained throughout the study until completion of all study visits.
Exclusion Criteria:
- Participants should not be receiving chemotherapy currently, or have received chemotherapy in the 6 months prior to entering the study
- Active intracranial lesions (stable low grade glioma is acceptable)
- History of seizure disorder or epilepsy. History of a single seizure that occurred more than 12 months prior to enrollment is acceptable. History of febrile seizures if the last febrile seizure occurred more than 12 months prior to enrollment is acceptable. Recurrent, unprovoked seizures (epilepsy) is sufficient for exclusion.
- Major Depression, Bipolar Disorder, Conduct Disorder, Adjustment Disorder, other major Anxiety Disorders, or other developmental psychiatric diagnoses, based on history
- For females, pregnancy
- Implanted brain stimulator, vagal nerve stimulator, ventriculoperitoneal shunt, cardiac pacemaker, or implanted medication port
- Asthma (bronchospasm has been reported as occurring infrequently and unpredictably when NAC is used as a mucolytic agent)
- High risk of upper gastrointestinal hemorrhage. Examples: presence of esophageal varices or peptic ulcers
- Current use of MEKINIST (MEK-inhibitor) or use within 30 days
Sites / Locations
- Cincinnati Children's Hospital Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
No Intervention
N-Acetylcysteine (NAC)
Placebo
Single Visit/Non-Treatment Arm
Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3. Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg *Max dose not to exceed 2700mg/day (1350mg BID)
Each subject will be dosed with placebo for 8 weeks.
Based on preliminary data, an additional "Single visit, non-treatment" cohort will include 40 individuals with NF1 for a single "biomarker" study visit. These individuals will undergo motor function (PANESS) and brain-based measures (TMS, MRI-MRS, DTI) as biomarkers of impaired executive function (ADHD-RS; BRIEF-2; TOVA) but will not be assigned to receive NAC/Placebo.